345 related articles for article (PubMed ID: 37123010)
21. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Li C; Wan Z; Deng Q; Li Z; Wang Y
Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
Mi Y; Wang X
J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
24. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
Xing P; Jiang Z; Liu Y
BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis.
Chatterjee D; Mou SI; Sultana T; Hosen MI; Faruk MO
Sci Rep; 2024 Jan; 14(1):368. PubMed ID: 38172584
[TBL] [Abstract][Full Text] [Related]
26. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
27. KLK6 Functions as an Oncogene and Unfavorable Prognostic Factor in Bladder Urothelial Carcinoma.
Zhao K; Gao M; Lin M
Dis Markers; 2022; 2022():3373851. PubMed ID: 36193495
[TBL] [Abstract][Full Text] [Related]
28. Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model.
Mao X; Chen S; Li G
Aging (Albany NY); 2021 Feb; 13(5):6957-6981. PubMed ID: 33621953
[TBL] [Abstract][Full Text] [Related]
29. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
Song Z; Gui S; Xiao S; Rao X; Cong N; Deng H; Yu Z; Zeng T
Sci Rep; 2024 Feb; 14(1):3198. PubMed ID: 38332160
[TBL] [Abstract][Full Text] [Related]
30. A Novel Prognostic Signature Based on Ferroptosis-Related Genes Predicts the Prognosis of Patients With Advanced Bladder Urothelial Carcinoma.
Li X; Huang J; Chen J; Zhan Y; Zhang R; Lu E; Li C; Zhang Y; Wang Y; Li Y; Zheng J; Geng W
Front Oncol; 2021; 11():726486. PubMed ID: 34966666
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
Front Oncol; 2022; 12():724261. PubMed ID: 35237505
[TBL] [Abstract][Full Text] [Related]
32. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
33. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
35. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
Deng H; Cheng F; Cheng S
Aging (Albany NY); 2024 Mar; 16(6):5751-5771. PubMed ID: 38507521
[TBL] [Abstract][Full Text] [Related]
37. Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis.
Kang Y; Zhu X; Wang X; Liao S; Jin M; Zhang L; Wu X; Zhao T; Zhang J; Lv J; Zhu D
Front Oncol; 2021; 11():641184. PubMed ID: 33816287
[TBL] [Abstract][Full Text] [Related]
38. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
Sun S; Wang Y; Wang J; Bi J
J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
[TBL] [Abstract][Full Text] [Related]
39. Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.
Wang Y; Tang Y; Liu Z; Tan X; Zou Y; Luo S; Yao K
Sci Rep; 2024 Jan; 14(1):1216. PubMed ID: 38216619
[TBL] [Abstract][Full Text] [Related]
40. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
Li P; Qiao G; Lu J; Ji W; Gao C; Qi F
Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
